MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)

Status: Open to Accrual
Read More

DURABLE: Delayed or Upfront brain RAdiotherapy in treatment naïve lung cancer patients with asymptomatic or minimally symptomatic Brain metastases and rEarrangements

Status: Open to Accrual
Read More

Phase II study of adagrasib + stereotactic radiosurgery (SRS) for patients with metastatic KRAS G12C-mutated NSCLC with untreated brain metastases

Status: Open to Accrual
Read More

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Status: Open to Accrual
Read More

A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab
as Second Line Treatment for Small Cell Lung Cancer

Status: Open to Accrual
Read More

An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC

Status: Closed to Accrual
Read More

Induction durvalumab followed by chemoradiation and consolidation durvalumab (MEDI4736) for stage III non-small cell lung cancer

Status: Closed to Accrual
Read More

A Phase II Study of GT103 in Combination with Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

Status: Closed to Accrual
Read More

Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

Status: Closed to Accrual
Read More

A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363

Status: Closed to Accrual
Read More

A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

Status: Closed to Accrual
Read More